KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Other Non Operating Income (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of Other Non Operating Income data on record, last reported at -$74.5 million in Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 390.13% year-over-year to -$74.5 million; the TTM value through Dec 2025 reached -$12.2 million, down 2133.33%, while the annual FY2025 figure was -$12.2 million, 2133.33% down from the prior year.
  • Other Non Operating Income reached -$74.5 million in Q4 2025 per EBS's latest filing, down from -$3.7 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $69.7 million in Q1 2025 and bottomed at -$74.5 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$1.2 million, with a median of -$2.6 million recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: crashed 458.33% in 2022, then soared 2150.0% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$900000.0 in 2021, then soared by 844.44% to $6.7 million in 2022, then crashed by 31.34% to $4.6 million in 2023, then plummeted by 430.43% to -$15.2 million in 2024, then plummeted by 390.13% to -$74.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$74.5 million in Q4 2025, -$3.7 million in Q3 2025, and -$3.7 million in Q2 2025.